728x90
반응형
Dabigatran, rivaroxaban, apixaban, and edoxaban are associated with a relative risk reduction of 10% for death and approximately 50% for intracranial hemorrhage compared with warfarin ( Table 76-4 ). Overall, these agents are as or more effective and safer than warfarin for preventing stroke or systemic embolism in patients with atrial fibrillation ; for VTE these agents are probably no more effective than warfarin, but the risk of bleeding is somewhat lower. It is difficult to claim that one direct-acting oral anticoagulant is better than another based solely on indirect comparisons, although some have been better studied in specific types of patients ( Table 76-5 ).
REF. Goldman-Cecil medicine, 26th edition
728x90
반응형
